Related Experiment Video
Updated: May 15, 2026

In Silico Modeling Method for Computational Aquatic Toxicology of Endocrine Disruptors: A Software-Based Approach Using QSAR Toolbox
Published on: August 28, 2019
Oligo safety working group exaggerated pharmacology subcommittee consensus document
Doug Kornbrust1, Joy Cavagnaro, Arthur Levin
1Preclinsight, Reno, Nevada 89502, USA. preclinsight@yahoo.com
This consensus opinion outlines strategies for assessing adverse effects from exaggerated pharmacology of oligonucleotides (ONs). It focuses on host gene expression targeting ONs and provides guidance for safety studies and regulatory discussions.
Area of Science:
- Pharmacology and Toxicology
- Oligonucleotide Therapeutics
- Drug Safety Assessment
Background:
- Oligonucleotides (ONs) are a growing class of therapeutics with diverse mechanisms of action.
- Assessing potential adverse effects from exaggerated pharmacology is crucial for ON safety.
- Existing safety assessment strategies may need adaptation for ON-specific properties.
Related Concept Videos
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Drug Control Governance: Regulatory Bodies and Their Impact
Clinically Relevant Drug Product Specifications: Methods of Establishment
Toxicity Testing in Animals
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence